A Phase 4 interventional study of Piperacillin Sodium and Sulbactam Sodium in Respiratory Tract Infections and Urinary Tract Infections, sponsored by Xiangbei Welman Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-08.
Sponsored by Xiangbei Welman Pharmaceutical Co., Ltd · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Tract Infections with a site in China — 13 open to participants now, 15 under way, 3 of them phase 3. Respiratory Tract Infections · China.
Among the 40 studies in Respiratory Tract Infections with a site in China, this one is the 7th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2011, is one of 5 in phase 4, and was the 8th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →13 of the 40 studies in Respiratory Tract Infections with a site in China are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Fudan University · Sites in China
Ages 18+
Huashan Hospital · Sites in China
Joincare Pharmaceutical Group Industry Co., Ltd · Sites in China
Ages 18–45 · Healthy volunteers
Min-Tze LIONG · Sites in China, Malaysia
Ages 1 days–6 yrs
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,000 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 202 across the 30 interventional studies, 1,000 across the 10 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 40 have an industry lead sponsor. The 10 most frequent:
Xiangbei Welman Pharmaceutical Co., Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.
Xiangbei Welman Pharmaceutical Co., Ltd has 5 studies filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
5 of the studies in Respiratory Tract Infections with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07085858LanZhou UniversityStudy of the Preventive Effects and Mechanisms of Yeast β-Glucan on Upper Respiratory Tract Infections | 2026-12-31 |
| NCT06645665Shenzhen Shenxin Biotechnology Co., LtdA Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above | 2027-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Tract Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
Piperacillin sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis,the latter making irreversible competitive inhibition of β-lactamase.The antimicrobial effect of Piperacillin can be enhanced by the two combined. The compound specifically aims to the mechanism of bacterial resistance, extending the life of Piperacillin in the treatment-resistant pathogen infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug:xintemie 1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
Drug: Piperacillin Sodium and Sulbactam Sodium
Drug pages: Piperacillin · Sulbactam
1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
Also known as: xin te mie, te mie jun, xin ke jun
The rate of bacterial clearance
end of treatment of bacteriological efficacy(bactercial clearance) The fore-and-aft changes of clinical symptoms and signs after discontinuation of durgs
Time frame: two years
Number of participants with Adverse Events
the incidence(%)of allergies, skin rashes, shock,death, etc.
Time frame: two years
The record gives a start of Jul 2011, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Piperacillin · Sulbactam
Respiratory Tract Infections →
Xiangbei Welman Pharmaceutical Co., Ltd